Press release content from Globe Newswire. The AP news staff was not involved in its creation. Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study ... Myovant Sciences, Inc.January 26, 2021 GMT 84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year 82.8% average reduction from baseline on the Numerical Rating Scale for dysmenorrhea from 7.4 (severe pain) to 1.3 (mild pain) over one year Bone mineral density loss was minimal at Week 24 and remained stable through one year Data to be included in New Drug Application submission to U.S. Food and Drug Administration anticipated in first half of 2021